

Jeffrey Wolf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9341016/publications.pdf>

Version: 2024-02-01

8
papers

196
citations

1307594

7
h-index

1588992

8
g-index

9
all docs

9
docs citations

9
times ranked

439
citing authors

#	ARTICLE	IF	CITATIONS
1	Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 131-139.e1.	0.4	54
2	A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD19-positive Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 29-34.	0.4	53
3	Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2163-2171.	5.2	21
4	Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. <i>Blood Advances</i> , 2020, 4, 3295-3301.	5.2	20
5	Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 126.	17.0	19
6	Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma. <i>Blood Advances</i> , 2021, 5, 5344-5348.	5.2	16
7	A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2020, 61, 1211-1219.	1.3	10
8	Digital Life Coaching During Stem Cell Transplantation: Development and Usability Study. <i>JMIR Formative Research</i> , 2022, 6, e33701.	1.4	3